PF-06651600

Phase 3Small molecule

Pfizer

PF-06651600 is one of 132 small molecule programs targeting Cicatricial Alopecia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

131

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cicatricial AlopeciaActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

Ulcerative ColitisActive, not recruiting

Alopecia AreataActive, not recruiting

VitiligoActive, not recruiting

Cicatricial AlopeciaPhase 2

Active, not recruiting

Rheumatoid ArthritisPhase 2

Active, not recruiting

Ulcerative ColitisPhase 2

Active, not recruiting

Alopecia AreataPhase 3

Active, not recruiting

VitiligoPhase 2

Active, not recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

PF-06651600

Pfizer

Phase 3

2 2

Actemra

Rituxan

61 4

Orencia

Bristol-Myers Squibb

Preclinical

47 5

Remicade

OOrganon and Co

Preclinical

43 6

Kevzara

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

14 7

Ilaris

Novartis

Preclinical

3 8

Celexa

AbbVie

Preclinical

1 9

Cataflam

Novartis

Preclinical

—10

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Alopecia Areata4 trials

Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata

Completed· Pfizer logo

Pfizer·Phase 2·NCT02974868·142 enrolled

Long-Term PF-06651600 for the Treatment of Alopecia Areata

Active, not recruiting· Pfizer logo

Pfizer·Phase 3·NCT04006457·1,052 enrolled

PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA

Terminated· Pfizer logo

Pfizer·Phase 2·NCT04517864·71 enrolled

Show 1 more trial

PF-06651600 for the Treatment of Alopecia Areata

Completed· Pfizer logo

Pfizer·Phase 2/3·NCT03732807·718 enrolled

Single Dose2 trials

A STUDY TO EVALUATE THE EFFECT OF PF-06651600 ON PHARMACOKINETICS OF SINGLE DOSE SUMATRIPTAN IN HEALTHY PARTICIPANTS.

Completed· Pfizer logo

Pfizer·Phase 1·NCT04355845·10 enrolled

ESTIMATION OF THE EFFECT OF MULTIPLE DOSE PF-06651600 ON THE PHARMACOKINETICS OF SINGLE DOSE MIDAZOLAM AND EFAVIRENZ

Completed· Pfizer logo

Pfizer·Phase 1·NCT03762928·12 enrolled

Rheumatoid Arthritis2 trials

TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE

Completed· Pfizer logo

Pfizer·Phase 2·NCT04413617·460 enrolled

Study To Assess The Efficacy And Safety Of Pf-06651600 In Subjects With Rheumatoid Arthritis With An Inadequate Response To Methotrexate

Completed· Pfizer logo

Pfizer·Phase 2·NCT02969044·70 enrolled

Tics2 trials

Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single-Dose of PF-06651600 in Healthy Participants

Completed· Pfizer logo

Pfizer·Phase 1·NCT03821493·12 enrolled

Study to Evaluate the Effect of Repeat-Dose Rifampin on the Pharmacokinetics (PK) of PF-06651600

Completed· Pfizer logo

Pfizer·Phase 1·NCT04266509·12 enrolled

Moderate to Severe Crohn's Disease1 trial

Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease

Completed· Pfizer logo

Pfizer·Phase 2·NCT03395184·244 enrolled

13 more indications

Ulcerative Colitis1 trial

Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis

Completed· Pfizer logo

Pfizer·Phase 2·NCT02958865·319 enrolled

ART1 trial

Bioavailability Study of PF-06651600 Formulations in Healthy Participants

Completed· Pfizer logo

Pfizer·Phase 1·NCT04004663·12 enrolled

Cicatricial Alopecia1 trial

Ritlecitinib for Cicatricial Alopecia

Completed·EEmma Guttman·Phase 2·NCT05549934·50 enrolled

Renal Impairment1 trial

A Renal Impairment Study for PF-06651600

Terminated· Pfizer logo

Pfizer·Phase 1·NCT04037865·8 enrolled

Vitiligo1 trial

A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects

Completed· Pfizer logo

Pfizer·Phase 2·NCT03715829·366 enrolled

Statin1 trial

A Study of PF-06651600 Effect on Rosuvastatin Pharmacokinetics in Healthy Participants

Completed· Pfizer logo

Pfizer·Phase 1·NCT04092595·12 enrolled

Absorption1 trial

Study to Characterize Absorption, Distribution, Metabolism and Excretion of 14C PF-06651600 and to Evaluate the Absolute Oral Bioavailability and Fraction Absorbed of PF-06651600.

Completed· Pfizer logo

Pfizer·Phase 1·NCT03929510·6 enrolled

Hepatic Impairment1 trial

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of PF-06651600 in Subjects With Hepatic Impairment and Healthy Volunteers

Completed· Pfizer logo

Pfizer·Phase 1·NCT04016077·18 enrolled

Interaction1 trial

A DRUG-DRUG INTERACTION STUDY BETWEEN PF-06650833 AND PF-06651600 FOLLOWING MULTIPLE DOSES IN HEALTHY PARTICIPANTS

Completed· Pfizer logo

Pfizer·Phase 1·NCT03827668·15 enrolled

Adult1 trial

PHARMACOKINETIC CHARACTERIZATION OF PF-06651600 IN CHINESE ADULT PARTICIPANTS

Completed· Pfizer logo

Pfizer·Phase 1·NCT04634565·9 enrolled

Steroid1 trial

Effect of PF-06651600 on the Pharmacokinetics of Oral Contraceptive Steroids

Completed· Pfizer logo

Pfizer·Phase 1·NCT04018274·29 enrolled

Oral1 trial

A STUDY TO ESTIMATE THE EFFECT OF PF-06651600 ON THE PHARMACOKINETICS (PK) OF ORAL CONTRACEPTIVE (OC)

Completed· Pfizer logo

Pfizer·Phase 1·NCT03608241·12 enrolled

Unspecified4 trials

Bioavailability Study Of PF-06651600 In Healthy Subjects

Completed· Pfizer logo

Pfizer·Phase 1·NCT02684760·14 enrolled

Safety and Pharmacokinetic Study of PF-06651600 in Japanese Healthy Volunteers

Completed· Pfizer logo

Pfizer·Phase 1·NCT03232905·6 enrolled

Bioequivalence Study of PF-06651600 Capsules Relative to Tablets and Estimation of Food Effect on Capsules.

Completed· Pfizer logo

Pfizer·Phase 1·NCT04390776·164 enrolled

Show 1 more trial

PF-06651600 Taste Study.

Completed· Pfizer logo

Pfizer·Phase 1·NCT03916393·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 27 trial records for PF-06651600. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PF-06651600 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PF-06651600. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Pfizer

PF-06651600

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Alopecia Areata4 trials

Single Dose2 trials

Rheumatoid Arthritis2 trials

Tics2 trials

Moderate to Severe Crohn's Disease1 trial

Ulcerative Colitis1 trial

ART1 trial

Cicatricial Alopecia1 trial

Renal Impairment1 trial

Vitiligo1 trial

Statin1 trial

Absorption1 trial

Hepatic Impairment1 trial

Interaction1 trial

Adult1 trial

Steroid1 trial

Oral1 trial

Unspecified4 trials

References

Drug Info

Quick Facts

Related News